The combination of atorvastatin and ethanol is not more hepatotoxic to rats than the administration of each drug alone

Brazilian Journal of Medical and Biological Research

Volumn 40, Issue 3, 2007, Pages 343-348

  Ito, D T ^a   Molina, H M ^a   Andriolo, A ^a   Borges, Durval R ^a,b  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b NONE   (Brazil)

Author keywords

Alcohol; Atorvastatin; Hepatotoxic; Liver injury

Indexed keywords

ALANINE AMINOTRANSFERASE; ALCOHOL; ASPARTATE AMINOTRANSFERASE; ATORVASTATIN; BROMSULFOPHTHALEIN; LACTATE DEHYDROGENASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE MARKER; DRUG ALCOHOL INTERACTION; DRUG USE; ENZYME RELEASE; FEEDING; LIVER PERFUSION; LIVER TOXICITY; MALE; NONHUMAN; OXYGEN CONSUMPTION; RAT;

ANIMALIA; RATTUS;

EID: 33947144072     PISSN: 0100879X     EISSN: 1414431X     Source Type: Journal    
DOI: 10.1590/S0100-879X2007000300009     Document Type: Article

References (29)

1. Leren TP. Cascade genetic screening for familial hypercholesterolemia. Clin Genet 2004; 66: 483-487.
2. Ma J, Sehgal NL, Ayanian JZ, Stafford RS. National trends in statin use by coronary heart disease risk category. PLoS Med 2005; 2: e123.
3. Zhou Z, Rahme E, Abrahamowicz M, Tu JV, Eisenberg MJ, Humphries K, et al. Effectiveness of statins for secondary prevention in elderly patients after acute myocardial infarction: an evaluation of class effect. CMAJ 2005; 172: 1187-1194.
4. IMS Health. IMS reports 8 percent constant dollar growth in 2002 audited global pharmaceutical sales to $400.6 billion (site on the internet). Fairfield (CT): IMS Health. http://www.imshealth.com/ims/ portal/front/articleC/0,2777,6599_3665_69890098,00.html. Accessed January 2, 2006.
5. Lea AP, McTavish D. Atorvastatin. A review of its pharmacology and therapeutic potential in the management of hyperlipidaemias. Drugs 1997; 53: 828-847.
6. Tolman KG. The liver and lovastatin. Am J Cardiol 2002; 89: 1374-1380.
7. Chalasani N. Statins and hepatotoxicity: focus on patients with fatty liver. Hepatology 2005; 41: 690-695.
8. Pasternak RC, Smith SC Jr, Bairey-Merz CN, Grundy SM, Cleeman JI, Lenfant C. ACC/AHA/NHLBI clinical advisory on the use and safety of statins. Circulation 2002; 106: 1024-1028.
9. Black DM, Bakker-Arkema RG, Nawrocki JW. An overview of the clinical safety profile of atorvastatin (lipitor), a new HMG-CoA reductase inhibitor. Arch Intern Med 1998; 158: 577-584.
10. Downs JR, Clearfield M, Tyroler HA, Whitney EJ, Kruyer W, Langendorfer A, et al. Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TEXCAPS): additional perspectives on tolerability of long-term treatment with lovastatin. Am J Cardiol 2001; 87: 1074-1079.
11. Borges DR, Kouyoumdjian M. The recognition site for hepatic clearance of plasma kallikrein is on its heavy chain and is latent on prokallikrein. J Hepatol 1992; 16 : 115-121.
12. Nakad A, Bataille L, Hamoir V, Sempoux C, Horsmans Y. Atorvastatin-induced acute hepatitis with absence of cross-toxicity with simvastatin. Lancet 1999; 353: 1763-1764.
13. Ridruejo E, Mando OG. Acute cholestatic hepatitis after reinitiating treatment with atorvastatin. J Hepatol 2002; 37: 165-166.
14. Wierzbicki AS, Crook MA. Cholestatic liver dysfunction. Lancet 1999; 354: 954.
15. Pelli N, Setti M. Atorvastatin as a trigger of autoimmune hepatitis. J Hepatol 2004; 40: 716.
16. Perger L, Kohler M, Fattinger K, Flury R, Meier PJ, Pauli-Magnus C. Fatal liver failure with atorvastatin. J Hepatol 2003; 39: 1095-1097.
17. Waters DD. Safety of high-dose atorvastatin therapy. Am J Cardiol 2005; 96: 69F-75F.
18. Gaist D, Rodriguez LA, Huerta C, Hallas J, Sindrup SH. Lipid-lowering drugs and risk of myopathy: a population-based follow-up study. Epidemiology 2001; 12: 565-569.
19. Mukamal KJ, Conigrave KM, Mittleman MA, Camargo CA Jr, Stampfer MJ, Willett WC, et al. Roles of drinking pattern and type of alcohol consumed in coronary heart disease in men. N Engl J Med 2003; 348: 109-118.
20. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360: 7-22.
21. Anonymous. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med 1998; 339: 1349-1357.
22. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, Macfarlane PW, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995; 333: 1301-1307.
23. Alsheikh-Ali AA, Ambrose MS, Kuvin JT, Karas RH. The safety of rosuvastatin as used in common clinical practice: a postmarketing analysis. Circulation 2005; 111: 3051-3057.
24. LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005; 352: 1425-1435.
25. Sever PS, Dahlof B, Poulter NR, Wedel H, Beevers G, Caulfield M, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial - Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003; 361: 1149-1158.
26. Pedersen TR, Kjekshus J, Berg K, Haghfelt T, Faergeman O, Faergeman G, et al. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). 1994. Atheroscler Suppl 2004; 5: 81-87.
27. Newman CB, Palmer G, Silbershatz H, Szarek M. Safety of atorvastatin derived from analysis of 44 completed trials in 9,416 patients. Am J Cardiol 2003; 92: 670-676.
28. Smith CC, Bernstein LI, Davis RB, Rind DM, Shmerling RH. Screening for statin-related toxicity: the yield of transaminase and creatine kinase measurements in a primary care setting. Arch Intern Med 2003; 163: 688-692.
29. Prasad JS, Crankshaw DL, Erickson RR, Elliott CE, Husby AD, Holtzman JL. Studies on the effect of chronic consumption of moderate amounts of ethanol on male rat hepatic microsomal drug-metabolizing activity. Biochem Pharmacol 1985; 34: 3427-3431.